Back to search results

G7 Dual Mobility Hip System for Hip Osteoarthritis and Other Joint Conditions

This study is looking at two types of hip replacement systems, the G7 Dual Mobility with Vivacit-E bearing and the G7 Dual Mobility with Longevity bearing. These systems are designed to help prevent hip dislocation after surgery. The study aims to confirm how safe and effective these systems are over the long term. You might be able to join if you are between 18 and 80 years old, need a total hip replacement, and have conditions like osteoarthritis, rheumatoid arthritis, or avascular necrosis (bone tissue death due to lack of blood supply). The study will follow participants for 10 years to see how well the implants work and how safe they are. The current status of the study is unclear.

Study design
This is a global study involving up to 358 participants who will receive one of the two G7 Dual Mobility hip systems. It is a non-randomized study, meaning participants are not randomly assigned to a treatment group.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 10 years to assess the survival and safety of the implant system.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05548972

G7 Dual Mobility With Vivacit-E or Longevity PMCF

Enrolling by Invitation
NAAges 18–80InterventionalTreatment
Zimmer Biomet
~358 participants
Updated 2025-06-15 on ClinicalTrials.gov
What's tested:G7 Dual Mobility with Vivacit-E bearingG7 Dual Mobility Longevity bearing

At a glance

Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Survival of the implant system
Measured over 10 years
+1 more outcome measured

Conditions

Hip Osteoarthritis
Rheumatoid Arthritis
Joint Diseases
Avascular Necrosis
Dislocation, Hip
Femoral Neck Fractures
Trochanteric Fractures
Revision Surgeries

Explore related trials

Avascular NecrosisFracture of neck of femurFunctional DeformityHip DislocationHip OsteoarthritisNon-unionOsteoarthritisRevision of hip arthroplastyRheumatoid ArthritisTotal replacement of hipTrochanteric Fractures

NCT05548972

Where you'd take part

This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Bowen Hefley Orthopedics

    Little Rock, Arkansasno site contact published

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Koreano site contact published

  • HCA HealthONE Orthopedic Specialists

    Denver, Coloradono site contact published

  • Hospital for Special Surgery

    New York, New Yorkno site contact published

  • Istituto San Siro

    Milan, Italyno site contact published

  • Jersey City Medical Center

    Jersey City, New Jerseyno site contact published

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam, South Koreano site contact published

  • Slocum Research & Education Foundation

    Eugene, Oregonno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Hassan Achakri · STUDY_DIRECTOR · Zimmer Biomet

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient is 18 to 80 years of age, inclusive
Patient is skeletally mature
Patient qualifies for (total) hip arthroplasty based on physical exam and medical history including at least one of the following:
Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
Rheumatoid arthritis
Dislocation risks
Correction of functional deformity
Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
Revision procedures where other treatment or devices have failed.
Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
Patient, or the patient's legally authorized representative (LAR), has participated in the Informed Consent process and is willing and able to sign an IRB/EC approved Informed Consent

Exclusion

Patient is septic, has an active infection or has osteomyelitis at the affected joint
Patient has significant osteoporosis as defined by treating surgeon
Patient has metabolic disorder(s) which may impair bone formation
Patient has osteomalacia
Patient has distant foci of infections which may spread to the implant site
Patient has rapid joint destruction, marked bone loss or bone resorption apparent on pre-operative radiographs
Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
Patient is undergoing simultaneous bilateral THA
Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which are likely to jeopardize the outcome of the surgery.
Patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
Patient is known to be pregnant
The patient is in a vulnerable population group such as:
a prisoner
a known alcohol or drug abuser
mentally incompetent or unable to understand what participation in this study entails

What this trial measures

  • Survival of the implant system10 years

    Survival of the implant system based on removal of the study device

  • Safety of the implant system10 years

    Safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.